Capecitabineand mitomycin C (MMC) is an active regimen for patients with metastatic colorectal carcinoma (MCRC) resistant to 5FU and irinotecan

被引：0
|
作者：
Rao, S [1 ]
Cunningham, D [1 ]
Ross, PJ [1 ]
Price, T [1 ]
Ward, C [1 ]
Norman, AR [1 ]
Hill, ME [1 ]
机构：
[1] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 50 条
  • [21] Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU - A phase 2 study
    Carlomagno, C
    Lauria, R
    De Laurentiis, M
    Arpino, G
    Massarelli, E
    Ferrara, C
    Milano, A
    Lombardi, AV
    Costanzo, R
    Catalano, G
    Bianco, AR
    De Placido, S
    ONCOLOGY, 2002, 63 (03) : 219 - 225
  • [22] Phase II study of oxaliplatin (OHP) and protracted 5-fluorouracil (5FU) infusion in pretreated metastatic colorectal cancer (MCRC) patients
    Mini, E
    Pinto, C
    Angelelli, B
    Dentico, P
    Piana, E
    Nobili, S
    Gentile, AL
    Scicolone, S
    Mazzei, T
    Martoni, A
    ANNALS OF ONCOLOGY, 2000, 11 : 73 - 73
  • [23] The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (GONO).
    Falcone, A.
    Masi, G.
    Brunetti, I.
    Benedetti, G.
    Bertetto, O.
    Picone, V.
    Chiara, S.
    Merlano, M.
    Vitello, S.
    Ricci, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 149S - 149S
  • [24] Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC):: CALGB 80203 preliminary results.
    Venook, A.
    Niedzwiecki, D.
    Hollis, D.
    Sutherland, S.
    Goldberg, R.
    Alberts, S.
    Benson, A.
    Wade, J.
    Schilsky, R.
    Mayer, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 148S - 148S
  • [25] Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    Chong, G
    Dickson, JLB
    Cunningham, D
    Norman, AR
    Rao, S
    Hill, ME
    Price, TJ
    Oates, J
    Tebbutt, N
    BRITISH JOURNAL OF CANCER, 2005, 93 (05) : 510 - 514
  • [26] Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    G Chong
    J L B Dickson
    D Cunningham
    A R Norman
    S Rao
    M E Hill
    T J Price
    J Oates
    N Tebbutt
    British Journal of Cancer, 2005, 93 : 510 - 514
  • [27] TREATMENT OF METASTATIC COLORECTAL-CARCINOMA WITH 5-FU, MITOMYCIN, VINCRISTINE, AND METHOTREXATE
    BECK, TM
    CURTIS, PW
    WOODARD, DA
    HART, NE
    SMITH, CE
    CANCER TREATMENT REPORTS, 1984, 68 (04): : 647 - 650
  • [28] COMBINATION MITOMYCIN-C (MMC) AND 5-FLUOROURACIL (5FU) THERAPY ADJUNCTIVE TO HIGH-RISK TRABECULECTOMY
    LIN, SA
    KIM, SY
    SINGH, K
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1995, 36 (04) : S86 - S86
  • [29] Plasma deoxyuridine levels in metastatic colorectal cancer (mCRC) patients and clinical response after 5FU based therapy in combination with arfolitixorin
    Taflin, Helena Anna
    Odin, Elisabeth
    Carlsson, Goran Ulf
    Tell, Roger
    Gustavsson, Bengt
    Wettergren, Yvonne
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [30] A phase II study with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) in patients with metastatic colorectal cancer
    Destefanis, M
    Dalla Mola, A
    Ostellino, O
    Capello, C
    Milanesi, E
    Grillo, C
    Castiglione, F
    Venturino, A
    Porcile, G
    ANNALS OF ONCOLOGY, 2000, 11 : 67 - 67
12345